Sanfilippo Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Retinal Phenotype in Mucopolysaccharidosis Type III.
Sieg Emma et al. — American journal of ophthalmology (9 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41812850/
- 2.
Sanfilippo syndrome type A with acute metabolic acidosis: a case report of the first documented SGSH c.571G > A homozygous mutation.
Zou Haiying et al. — BMC pediatrics (26 February 2026)
https://pubmed.ncbi.nlm.nih.gov/41742100/
- 3.
Evaluation of GlcNAc-Configured Glycomimetics as Pharmacological Chaperones of NAGLU for the Treatment of Mucopolysaccharidosis IIIB.
Ballout Nissrine et al. — Biomolecules (16 February 2026)
https://pubmed.ncbi.nlm.nih.gov/41750382/
- 4.
Sanfilippo syndrome (mucopolysaccharidosis type III)
Mostafa Mohamed — Radiopaedia.org (9 February 2026)
https://doi.org/10.53347/rid-229022
- 5.
Healthcare resource use for mucopolysaccharidosis type III (MPS III) patients in the United States based on analysis of claims data
Karen Bean et al. — Molecular Genetics and Metabolism (1 February 2026)
https://doi.org/10.1016/j.ymgme.2025.109330
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
Recruiting — Phase 2 — Denali Therapeutics Inc.
https://clinicaltrials.gov/study/NCT05371613
- 2.
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Recruiting — Phase 3 — Novo Nordisk A/S
https://clinicaltrials.gov/study/NCT06118281
- 3.
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Recruiting — Phase 2 — Ultragenyx Pharmaceutical Inc
https://clinicaltrials.gov/study/NCT02716246
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Sanfilippo Syndrome
Sanfilippo syndrome (MPS III) is a rare lysosomal storage disorder caused by enzyme deficiencies that result in heparan sulfate accumulation in cells. It causes progressive neurodegeneration, intellectual regression, and behaviour problems in childhood. Australian families have been pivotal in advocating for gene therapy research.
Most Recent Research
BACKGROUND: Mucopolysaccharidosis type III (MPSIII, Sanfilippo syndrome) is a group of rare, hereditary, autosomal recessive, lysosomal storage disorders characterized by neurocognitive decline and early mortality. Pronounced visual impairment is frequent and retinal disease is more common in MPS III than in other MPS subtypes. The aim of this study was to characterize the retinal phenotype in MPS III using retinal imaging to provide insights into disease course. DESIGN: Retrospective monocenter case series METHODS: In this study, 27 patients with genetically confirmed MPS III (n=16 MPS IIIA; n=9 MPS IIIB; n=2 MPS IIIC) were included. The disease phenotype was classified as rapid progressive or slowly progressive. All patients underwent spectral-domain optical coherence tomography (SD-OCT) imaging to analyze central retinal thickness, peripapillary retinal nerve fiber layer thickness (RNFL) and configuration of retinal layers. Depending on the neurocognitive status and compliance, best-corrected visual acuity (BCVA), slit lamp microscopy and fundoscopy were performed. RESULTS: The median age at the ophthalmological examination was 6.5 years (range 1-16 years). Slit-lamp examination was usually unremarkable. BCVA was assessable in 6 out of 27 patients and was within the normal age-adjusted range. Parafoveal degeneration of the outer retinal layers was observed in 59% of patients, while foveal thickening of the external limiting membrane was noted in 67%. One MPS IIIA patient showed severe foveal atrophy, and another presented with foveal intraretinal fluid accumulation. Quantitative retinal thickness analysis of all patients showed median values at the lower end of the reference spectrum in the inner perifoveal ring and below the normal range in the outer perifoveal ring, with no distinct pattern that distinguishes the subtypes or phenotypes. RNFL thickness was unremarkable in all patients. CONCLUSION: This study reveals a pattern of parafoveal degeneration of outer retinal layers in all 3 MPS III subtypes, of which MPS IIIA patients, known to have a more rapidly progressive neurocognitive disease, show the most severe retinal involvement. We provide natural history data that may contribute to planning and conducting future clinical trials, and we recommend further systematic ophthalmological examinations of MPS III patients to evaluate ocular affection.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.